TīmeklisRenovoRx is a clinical-stage biopharmaceutical company focused on fighting cancer through the localized treatment of difficult to treat tumors via our proprietary … Tīmeklis2024. gada 15. aug. · IPO Pricing Los Altos, California-based RenovoRx, Inc. (NASDAQ:RNXT) has filed for offering up to 1.85 million units of securities in an …
RenovoRx Announces Third Quarter 2024 Financial Results
Tīmeklis2024. gada 25. aug. · RenovoRx, Inc. has completed an IPO in the amount of $16.65 million. Security Name: Units Security Type: Equity/Derivative Unit Securities … TīmeklisRenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for lead... credit card bad no
RNXT Stock Price RenovoRx Inc. Stock Quote (U.S.: Nasdaq ...
Tīmeklis2024. gada 31. dec. · Closed on IPO and listed on the Nasdaq Capital Market under the ticker symbol, “RNXT.” Received new 510(k) clearance for the RenovoCath® delivery system (the device component of the Company’s initial product, RenovoGem™). RenovoRx received its initial 510(k) for the RenovoCath delivery system in 2014. TīmeklisRenovoRx Inc is a clinical-stage biopharmaceutical company. It is focused on developing therapies for the local treatment of solid tumors and conducting a Phase 3 registrational trial for lead product candidate RenovoGem. Contact Information Website www.renovorx.com Ownership Status Publicly Held Financing Status Formerly VC … Tīmeklis2024. gada 15. nov. · Los Altos, CA, November 15, 2024 – RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today reported its unaudited financial results for the third quarter ended September 30, 2024. “The third quarter of 2024 marked an important juncture in the growth of our … buckhannon 10 day forecast